Albireo Submits for U.S. FDA and EMA Product Approval of Once-Daily Odevixibat for PFIC

BOSTON, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced it has submitted a New Drug Application (NDA) to...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news